Trial site management in the post pandemic era
The impacts of 2020 on trials are causing pharma to consider a new direction for trial sites, taking them closer to the patient
Close log in window
Broader and deeper outreach, along with RWE, are some of the methods pharma is using to widen trials participation
The Tigerlily Foundation President and Founder is more hopeful than ever that she can help pharma give Black women the representation they d...
Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline producti...
Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about t...
